

## RNA TUMOR VIRUSES

let genes  
 on board  
 env  
~~not~~ pot  
 +IC

## I. Introduction

General Reviews: "The molecular biology of tumor viruses",  
Ed. J. Tooze, Cold Spring Harbor Laboratory (1973).

Plan

Stress: RNATV's as tools for  
understanding: (of Cancer program)  
oncogenes  
gene expression + reg  
homologous  
evolution  
information transfer  
recombination

No. 1 up.

Begin i some facts →  
then except for oncogene.  

- replication
- messenger genome
- regulation of viral gene exp.
- Transformation
- eukaryotic viruses
- human agents.

Bishop, J.M. and Varmus, H.E., "The molecular biology of RNA tumor viruses", Cancer: A Comprehensive Treatise 2:3-48 (1975).

Bader, J.P., "Reproduction of RNA tumor viruses", Compr. Virol. 4:253-332 (1975).

Hanafusa, H., "Avian RNA tumor viruses", Cancer: A Comprehensive Treatise 2:49-90 (1975).

Lieber, M. M. and Todaro, G.M., "Mammalian type C RNA viruses", Cancer: A Comprehensive Treatise 2:91-130 (1975).

Moore, D.H., "Mammary tumor virus", Cancer: A Comprehensive Treatise 2:131-167 (1975).

Temin, H.M., "Mechanism of cell transformation by RNA tumor viruses", Ann. Rev. Microbiol. 25:609-648 (1971).

Cold Spring Harbor Symposium Quant. Biol. 39,  
Vol 2 (1975).

ICN-UCLA Symposium on Molecular & Cellular Biology, Vol. IV (1975).

A. A brief history of RNA tumor virology: Ellerman and Bang & ALV  
 Rous → RSV (ASV)  
 Bittner and MMTV  
 Gross and MuLV  
 (Gross, Oncogenic Viruses, Permagon Press, 1970)

B. Morphology and chemistry of virus particles (Table 1) ● C-type (+ bud)  
 RnT TV's all similar  
 despite wide distribution + wide biological potential  
 . emphasis on ASV + mutants  
 ● B-type  
 ● budding

C. Definitions of biological behavior/in vitro (Tables 2 & 3)

---transformation and focus assay

Term + Rubin

---permissive vs. non-permissive cells (SV40)  
 high eff. low eff.

---replication-defective and transformation-defective viruses

note transp function apparently  
 not req. for replication (SV40)

II. Replication

A. Absorption and penetration: surface determinants of host range - cell receptors and virus envelope glycoproteins (Tables 4 & 5)

Suscept. dominant - phenotypic mixing  $\rightarrow$  virus infections  
 cell gene env - noninfectious  $\rightarrow$  host antigen

ENV

B. The basis for the provirus hypothesis (Temin, H.M., Science 192:1075, 1976; Temin, PNAS 69:1016, 1972).

---Inhibitor experiments

ss R.V.  $\rightarrow$  ds DNA  $\rightarrow$  int.  
 R.V.  $\rightarrow$  ss R.V.

---BUdR sensitizes the viral genome to light (Boettiger & Temin, Nature 226:1211, 1970).

C. Reverse transcriptase (Reviews: Temin, H.M. and Baltimore, D., Adv. Virus Res. 17:129, 1972; Sarngadharan, M.G., Allaudeen, H.S. and Gallo, R.C., Methods in Cancer Research 7:426, 1976; Green & Gerard, Progress in Nucleic Acid Res. 14:188, 1974; also forthcoming reviews by Verma, Taylor, and Weinberg in BBA Reviews in Cancer, 1977).

Vaccinia DNA  $\rightarrow$  RNA into  
 rec  $\leftarrow$  precedents for virion associated polymerases  
 E. coli (Sigma Nucleic acid)  
 Hybrid (Endo)  $\leftarrow$  (Exo)

---direct demonstration of viral DNA in infected cells:  
 -nucleic acid hybridization (Neiman, Science 178:750, 1972)  
 -transfection (Hill & Hillock, Virology 49: 309, 1972)

---is reverse transcriptase a viral gene product?

-early coordinate ts mutants (Verma, Mason, Drost & Baltimore, Nature 251:27, 1974) and deletion mutants (Hanafusa et al., Science 177:1188, 1972)

---how does reverse transcriptase work in vitro?


(1) physical structure, three enzymatic activities, templates, and primers

recently purified: L.B. ASV; 70K MuLV

60K-80K

3 acts: RNA  $\rightarrow$  DNA (Arc: dG (vs cell DNA polymerase))  
 DNA  $\rightarrow$  DNA (gap fill - heiko - no displacement)  
 RNAse H  
 DNA polymerase  
 DNA binding  
 exo, jumping

(2) utility for molecular biologists




# Lecture 2

3

Early - repetitive copying  
short pieces

1° product ~ 100<sup>+</sup> bases



(3) problems posed by the natural template: primer (Taylor et al., ICN-UCLA Symposium IV, p. 161, 1976; Haseltine & Baltimore, ICN-UCLA Symposium IV, p. 175, 1976)

---location of the primer near the 5' end

---"short stop" DNA (for sequence, see Shine et al., and Maxam et al., PNAS, in press 1977)

---the "transcriptional leap"

---terminal redundancy

---making full length cDNA (Rothenberg & Baltimore, J. Virol. 21:168, 1977)

- optimizing conditions  
- ? note problem with nucleic acid

---initiating the second ("plus") strand mode, but how? - not beginning - ? template or primer

---how does reverse transcriptase work in vivo?

synthesis in 1st 6 hrs. - Few copies - detect with hybridization

④ in enucleated cells. -  
primer for 1st strand prob tRNA<sup>Trp</sup>



synthesis in the cytoplasm (Varmus et al., PNAS 71:3874, 1974)

Forms of DNA: permuted linear with fragmented plus strands

Form I - Classical linear.  
as in SV40

EM p purification ~ 10<sup>6</sup> fold

vDNA is infectious.

X covalently closed circles in nucleus (Guntaka et al., Nature 253:507, 1975 and J. Mol. Biol. 106:337, 1976)

## D. Integration

? get back "x" ~~OMIT~~ ---requirements and mechanisms

No excision! propagation } of  
? cell site } viruses /

---the Fv-1 story: N tropic vs. B tropic viruses (Review:  
OMITTED Lilly & Pincus, Adv. Canc. Res. 17:231, 1973) (Table 5)

N-tropic MuLV + VSV in NIH Swiss → ~~VSV(VSV)~~ VSV pseudotypes reveal intracellular block

replicate in BAE/IC as well as NIH3T3

MSV(MuLV-N) (Huang et al., J. Virol. 12:659, 1973)

Mice & man.  
Neurons in B cells

vDNA not mech.  
but ↓ mech. — Note MSV requires tropism

RH ↓ target protein viral protein? RTase? purifying fractions, fractionation, for C → N transport

impaired integration (Jolicove & Baltimore, PNAS 73:8, 1976)

22S

OMIT

---is an integrated template required? EB


Fv-1

---host RNA polymerase II is responsible (Rymo et al., PNAS 71:2782, 1974)

---what is/are primary transcript(s)? (see below, IV)  
Consider further after discussing genes + their order


## F. Translation, assembly, budding of virus, transformation

⊕ ← Summary: \* \* \*




### III. The viral genome

A. Definition of its structure: physicochemical analysis: subunits and low molecular weight RNA's



electron microscopy shows 5'-5' linkage of subunits (Bender & Davidson, *Cell* 7:595, 1976; Kung et al., *J. Virol.* 16:397, 1975)



B. The subunits are identical: T1 oligonucleotide fingerprinting (Beeman et al., *PNAS* 71:4254, 1974; Billeter et al., *PNAS* 71:3560, 1974)

A<sub>100-200</sub> A<sub>04</sub>

C. Additional structural features: poly(A) at 3' end (Wang & Duesberg, *J. Virol.* 14:1515, 1974); capped 5' end (7mGpppG<sup>m</sup>pCp---) (Furuichi et al., *Nature* 257:618, 1975); primer (see above, II C)

### D. Genes and their definition

---pol (see above) - ts mutants - also has major structural genes

XX ---gag: ts mutants (Hunter et al., *Virology* 69:35, 1976) and translation *in vitro* (see below, IV B)

---env: deletion mutants (Kawai & Hanafusa, *PNAS* 70:3493, 1973)  
host range determinants (Table 4)  
RNA ↓ 21%

---src: ts and deletion mutants (Martin, *Nature* 277:1021, 1970;  
 $\alpha = b + x$       RNA ↓ 16%.      Vogt, *Virology* 46:939, 1971)  
ASV → ts ASV

### E. Mapping

high rate recombination mapping  
ts T vs td → no wt  
ts T vs ts T → wt - gene distance  
---genetic recombination (Kawai & Hanafusa, *Virology* 49:37, 1972;  
Bernstein et al., *Virology* 70:206, 1976)


(distance from poly A to deletion specific oligo:  
Electron spin resonance:  
---oligonucleotide mapping (with deletion mutants, recombinants)  
(Duesberg et al., ICN-UCLA Symposium IV, p. 107, 1976; Wang et al., *PNAS* 73:3952, 1976)

+ src ts

---heteroduplex mapping (Junghans et al., *PNAS*, in press)  
Common 1000 bases  
ASV c DNA + td RNA 16kb 1kb

---restriction endonuclease mapping (Shank et al., unpublished)

				SgsTS	Distance	Conclusion
src	+	-	27.1	1	500-2000	Conform point.
env	C	B	C	1	2500-5000	
pol	ts	wt	wt	1 or 2	6000-8000	Deduced point.
gag	p27-1	p27-2	27-2	2	8000-10000	Establish point.



#### IV. Gene expression and regulation

gas - 322/u.  
env - 522/u  
src - 52/u  
src - ?

##### A. Problems in permissive cells: differing amounts of gene products

~~single initiation~~ → internal cistrons

~~per m R.U. in env~~ → multiple promoters & T. processing of RNA (src)

##### B. Experimental approaches

SV40

TMV

Sindbis

or protein (eg. pol)


---size and sequence composition of viral RNA's (Bishop et al., ICN-UCLA Symposium VI, p. 1, 1976; Weiss, Baker et al., unpublished)

---immunoprecipitation of polyribosomes (Mueller-Lantzsch and Fan, Cell 9:579, 1976)

---analysis of products of translation in vivo and in vitro (Vogt et al., J. Mol. Biol. 96:471, 1975; Pawson et al., J. Virol. 19:950, 1976; Oppermann et al., unpublished)

##### C. The tentative model: precedents and problems

precedents  
program vs. transcription  
35S SV40 vs. 28S RNA  
read through RNA -? No 28S  
Nuclease



D. Blocks to viral gene expression in non-permissive cells

- label cells → immunoprecipitation  
35S viral → 176K → cleave to gag  
internal 186K → src + tryptic, of gag + pol  
28S intracellular → p70  
21S

E. The mechanisms of reversion (Frankel et al., Science 191:1264, 1976; Deng et al., Virology 76:313, 1977; 65:522, 1974)

loss of genome mutation src gene  
↓  
src RNA  
↓  
? later cell resistance -? other

F. A model for study of hormone action: glucocorticoids regulate the rate of synthesis of MMTV RNA (Young et al., J. Virol. 21:139, 1977; Ringold et al., submitted to PNAS)

OMIT  
(Keith covered it)

? ammonia from hormone resp. site

Put into hetero host  
still under src control

X. Transforming genes

Review

A. Definition and functions of the avian src gene

cytoskeleton + changing perception of "cytosol" + membrane fluidity

not req. for reg.  
? gene product  
defined specificity

B. Manifestations of transformation of fibroblasts by the src gene:

Ash: fibroblast morph  
of actin  
of myosin  
concept.

to SR-A/fk: morph  
of actin  
of tubulin

? effect on cytoskeleton: note T.Guy  
OMIT

xupt - nuclear envelope to myoblast: ↑ ↓ → "Th" cytoplasm

necessary

C. The transforming gene prevents differentiation of myoblasts (Holtzer et al., PNAS 72:4051, 1975)

NR Myoblast  
on ASV (ST410)

→ myotubes (post mitotic, TCFK)

myoblast + AV

on AT & ST35

→ differ. myotubes, → differ. omitt

Th myoblast

| if Th myoblast has to src

| 40°

but differentiation (30° → degeneration)  
∴ no src leads to diff. cell; delay diff. of precursors -

$\{$  CEF(-) } in amelanotic RBT to  $\{$  c-Myc  $\}$   $\rightarrow$  oncogene  
 $\{$  t<sub>1</sub> ASV CEF(-) }  $\rightarrow$  oncogene  
ASV CEF (+)  $\} \rightarrow$  oncogene & mRNA's

- D. The transforming gene activates transcription of embryonic globin genes (Groudine & Weintraub, PNAS 72:4464, 1975)

$\rightarrow$  embryonic  $\{$  src  $\rightarrow$  sarcoma, rare form of human cancer  
 $\&$  breast transforms (B) by myeloma, in vitro  $\} \rightarrow$  oncogene mediated  
MC 29 " myeloid precursor"  $\} \rightarrow$  oncogene  $\{$  Many other types of oncogenes mediated  
AEV " Burkitt"  $\} \rightarrow$  oncogene  $\{$  virus  $\}$   $\rightarrow$  oncogene  $\{$  viruses  
note Fe synth: myeloblasts  
phase cytide  $\rightarrow$  oncogene separation

## VI. Endogenous viruses

- A. The evidence for the oncogene-virogene hypothesis (Todaro & Huebner PNAS 69:1009, 1972)  $\{$  NC cells have real Ag's, viral DNA

~~— virogene, oncogene~~  
~~independently regulated~~

- B. Properties of endogenous viruses

OMIT

- C. Mapping the chromosomal site of an endogenous murine leukemia virus (Chattopadhyay et al., PNAS 72:906, 1975)

removing pellucency  $\rightarrow$  overcomes organotropism of MuLV in infected new borns ( $\rightarrow$  genetic trans.)  
4 full pregnancies  $\rightarrow$  leukemia D.  
MuLV  $\rightarrow$  leukemia +  
♀ X ♂  $\rightarrow$  germ line transmission  $\downarrow$   
♂ X ♀  $\rightarrow$  (50%  $\rightarrow$  in leuke)  
↓ SVL ♂ SVL ♂ E.  
♂ ♂ X ♀  $\rightarrow$  F.  
MuLV  $\rightarrow$  Virus prod ( $\rightarrow$  leuk)  
+ viral DNA  $\rightarrow$  lymphoid cell  
↓ retrovirus (dominant)  
Viruses considered defective  
but ? pale (of no apparent G.)  
but absent of BEV, RAV-O X

Trans-species spread of endogenous viruses: the RD-114 story (MacAllister et al., Nature N.B. 235:3, 1972; Benveniste & Todaro Nature 252:456, 1974) RD shepherds son mouse  $\rightarrow$  feline cat brain  $\rightarrow$  cat cells in cult  $\rightarrow$  RNA TV -  $\beta$ -cat vs human DNA (Rous) +  $\gamma$ -cat

similar virus induced feline cat, grossly different in human (Rous)  
As + RNA related  $\rightarrow$  by sequence in cat from feline. bovine - baboon  
Can endogenous viruses be used to study evolution?  $\downarrow$   
 $\downarrow$  e.g., interspecies

The baboon virus and the origin of man (Benveniste & Todaro, PNAS 71:4513, 1974; Nature 261:101, 1976)  
unique seq overall diverged in accord w/ evol. time, unrelated to geography.  
DNA seqs. related to BEV diverged as f (time + geography). man in African soil

What is the evidence for independently regulated oncogenes?

The origin of the avian src gene (Stehelin et al., Nature 260:170, 1976; Padgett et al., Cell, in press, 1977; Spector et al., unpublished; Varmus et al., ICN-UCLA Symposium IV, p. 339, 1976)  $\{$  src in all cells - but is it linked to virogene?  $\downarrow$  (No)

## VII. Do human RNA tumor viruses exist?

- A. Defining approaches in the context of RNA tumor viruses of animals.  $\{$  endogenous (? induce oncogene)  
- partial expression (in permissive cells); defective viruses  $\} \rightarrow$  detected  $\in$  animal virus reagents  $\{$  ±  $\}$

$\rightarrow$  viruses prod. by tumor cells.

- B. What is HL-23 virus, where did it come from and what has it done?

(Gallagher & Gallo, Science 197:350, 1974; Reitz et al., PNAS 73:2113, 1976; Okabe et al., Nature 260:264, 1976; Wong-Staal et al., Nature 262:190, 1976)

b1y. o E AML

budding viruses

propagated in culture

2 component  $\{$  BEV (C)  $\pm$  (IT)  $\} \rightarrow$  NEODA P75 et al.,  $\{$  + (W)  $\}$   $\rightarrow$  SSV(1) - -

Table 1

	<u>ASV</u>	<u>ALV (or td ASV)</u>	<u>MSV</u>	<u>MuLV</u>
<u>RNA subunit</u>	$3.3 \times 10^6$	$2.8 \times 10^6$	$1.9 \times 10^6$	$3 \times 10^6$
<u>Probable genes</u>	gag pol env src	gag pol env	gag src (?)	gag pol env
<u>Viral proteins</u>	gp85, gp37 RT ( $\alpha\beta$ ) p27, p19, p15 p12, p10	same as ASV	? (Found as pseudotype of MLV)	gp70, gp45 RT (1 subunit) p30, <del>p19</del> , p15 p15(E), p12, p10
<u>Biological effect in vivo</u>	Sarcomas	Leukosis, other tumors	Sarcomas	Leukemias
<u>Biological Assay</u>	Fibroblast Transformation	"Plaques" (some strains)	Fibroblast Transformation	Cell Fusion (XC cells)

Table 2

Biology of principal avian viruses

<u>Virus</u>	<u>Permissive (Avian) Cell</u>	<u>Non-Permissive (Mammalian) Cell</u>
nd ASV	T <sup>+</sup> R <sup>+</sup>	T <sup>+</sup> R <sup>-</sup>
td ASV (or ALV) (src <sup>-</sup> )	T <sup>-</sup> R <sup>+</sup>	T <sup>-</sup> R <sup>-</sup> } (no particles)
rd ASV (env <sup>-</sup> )	T <sup>+</sup> R <sup>-</sup> (non-infectious particles)	T <sup>+</sup> R <sup>-</sup>
td ASV + rd ASV	T <sup>+</sup> R <sup>+</sup> (phenotypic mixing)	T = transformation R = replication

Table 3

Biology of principal murine C-type viruses

<u>Virus</u>	<u>Permissive (Murine) Cell</u>
MuLV (td)	T <sup>-</sup> R <sup>+</sup>
MSV (rd)	T <sup>+</sup> R <sup>-</sup> (no particles)
MSV + MuLV	T <sup>+</sup> R <sup>+</sup> (phenotypic mixing)

ASV = avian sarcoma virus; ALV = avian leukosis virus

MSV = murine sarcoma virus; MuLV = murine leukemia virus

nd = non defective

td = transformation defective

rd = replication defective

Table 4

<u>Host Range</u>	<u>ASV env gene</u>				
	<u>A</u>	<u>B</u>	<u>C</u>	<u>D</u>	<u>E</u>
<u>Chicken Type</u>					
C/A	-	+	+	+	+
C/B	+	-	+	+	+
C/C	+	+	-	+	+
C/D	+	+	+	-	+
C/E	+	+	+	+	-
C/O	+	+	+	+	+

e.g. C/A = chicken "bars" subgroup A virus  
 C/O = "bars" nothing  
 + = susceptible


Table 5

<u>Host Range</u>	<u>MuLV Strains</u>			
	<u>Cell</u>	<u>N-tropic</u>	<u>B-tropic</u>	<u>Xenotropic</u>
Fv-1 <sup>aa</sup>	NIH Swiss Mouse	+	-	-
Fv-1 <sup>bb</sup>	BALB/c Mouse	-	+	-
	Human Cells	-	-	+
Fv-1 <sup>nb</sup>		-	-	-

∴ resistance dominant

Fv-1 chromosome II


# INFECTION OF A PERMISSIVE HOST BY AVIAN SARCOMA VIRUS




SYNTHESIS OF VIRUS-SPECIFIC RNA,  
ADDITION OF POLYADENYLATE,  
TRANSPORT TO CYTOPLASM  
(after 18 hours)

SYNTHESIS OF VIRAL PROTEIN IN POLYSOMES,  
CELL TRANSFORMATION, VIRAL ASSEMBLY  
AND RELEASE (after 24 hours)

*also page 2 much of DNA synth*




Mutations: — ● — | — ● — ● — **GP DELET. OSACRC** ● — AAA



functions:

Core proteins Antigens, assembly, RNA binding (p19)	Reverse transcription ( $\alpha \cdot \beta$ )	Envelope Host range Infectivity	Initiation + Maintenance of Transformation of Fibroblasts
---	---	---------------------------------------	---



## STRUCTURE AND FUNCTION OF THE AVIAN SARCOMA VIRUS GENOME